Michael Zasloff

Michael Zasloff

Company: Enterin, Inc

Job title: Co-Founder, CSO & Chairman


Professor of Pediatrics and Genetics, Georgetown University, Dean of Research and Translational Science at Georgetown University, founder of Magainin and former President Magainin Research Institute

Over the past 25 years, Dr. Zasloff’s scientific interests have centered on the innate immune systems of animals. Dr. Zasloff received his M.D.-Ph.D. in the Medical Scientist Training Program at New York University School of Medicine. In the 1980’s, Dr. Zasloff was Chief, Human Genetics Branch, National Institutes of Child Health and Human Development, at the National Institutes of Health. In 1988 Dr Zasloff founded Magainin Pharmaceuticals, Inc. a publicly traded biotechnology company. In the same year he joined the faculty of the University of Pennsylvania School of Medicine as the Charles E. H. Upham Professor of Pediatrics and Genetics, and assumed the position of Director of the Division of Human Genetics of the Children’s Hospital of Philadelphia.  In July 1992 Dr. Zasloff left Penn and joined Magainin on a full time basis, and served as Executive Vice President and President of the Magainin Research Institute, a basic research division of the Company. From July 1996 through November 2000 Dr. Zasloff was Vice Chairman of the Board of Magainin Pharmaceuticals.  In 2002, Dr. Zasloff was named Dean of Research and Translational Science at Georgetown, tasked with the integration of the basic science conducted at Georgetown with the clinical environment of the Medical Center. Between 2004 and 2006 Dr. Zasloff also served as Senior Vice President for Biotechnology for Ferris, Baker Watts, and an investment firm in D.C.

Since 2004, Dr. Zasloff has been actively engaged in studies of innate immunity as Scientific Director of the MedStar-Georgetown Transplant Institute.  His research interests remain focused on the role of antimicrobial peptides and aminosterols in health and disease, and application to the prevention and treatment of disease. He has published over 150 peer reviewed articles, and holds over 40 issued US patents.

He recently founded Enterin, Inc. where he serves as Chairman and CEO. He also serves as the lead independent Director on the Board of Amphastar Pharmaceuticals, Inc. and is a Director at Sarentis Therapeutics and Novo Therapeutics. He has received numerous awards including an honorary Doctor of Science from Georgetown University in 2011.


Clinical Experience of Targeting Alpha Synuclein in Enteric Nerves Produced in Response to Infection Over the Life Course to Treat Parkinson’s Disease 12:00 pm

• Exploring the underlying pathogenic pathways linking alpha synuclein and the enteric nervous system resulting from the aggregate impact of infection over the life course • Demonstrating clinical activity of ENT-01 in the treatment of Parkinson’s Disease • Ensuring clinical success – key takeaways for getting products into the clinicRead more

day: Day Two

Microbiome GBA Industry & Academic Leaders Panel Discussion – Providing an Overview of the Status & Direction of the Microbiome GBA Space 8:30 am

• Providing a bird’s eye view on scientific and product development progress made in the microbiome gut-brain axis space – what is the status of this field? • Reviewing gaps in our knowledge of neurogastroenterology and hot pockets of innovation opportunity in the microbiome-GBA space • Plotting the road to success: what is our end…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.